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        Ion channels are well recognized as important thera-
peutic targets for treating a number of different patho-
physiologies. Historically, however, development of 
drugs targeting this protein class has been diffi  cult. Sev-
eral challenges associated with molecular-based drug 
discovery include validation of new channel targets and 
identifi  cation of acceptable medicinal chemistry leads. 
Proof of concept approaches, focusing on combined 
molecular biological/pharmacological studies, have 
been successful. New, functional, high throughput 
screening (HTS) strategies developed to identify tracta-
ble lead structures, which typically are not abundant in 
small molecule libraries, have also yielded promising 
results. Automated cell-based HTS assays can be confi  g-
ured for many different types of ion channels using 
fl   uorescence methods to monitor either changes in 
membrane potential or intracellular calcium with high 
density format plate readers. New automated patch 
clamp technologies provide secondary screens to con-
fi  rm the activity of hits at the channel level, to deter-
mine selectivity across ion channel superfamilies, and 
to provide insight into mechanism of action. The same 
primary and secondary assays effectively support me-
dicinal chemistry lead development. Together, these 
methodologies, along with classical drug development 
practices, provide an opportunity to discover and opti-
mize the activity of ion channel drug development can-
didates. A case study with voltage-gated sodium channels 
is presented to illustrate these principles. 
  Introduction 
  Ion channels are important drug targets because they 
play a crucial role in controlling a very wide spectrum of 
physiological processes (  Hille, 2001  ), and because their 
dysfunction can lead to pathophysiology (  Ashcroft, 
2000  ). Given the strong historical precedent that exists 
for discovering and commercializing successful drugs 
that modulate the activity of voltage-gated sodium, cal-
cium, or potassium channels, or ligand-gated ion chan-
nels, new generations of therapeutic agents are expected 
to result from targeting this protein family. Early ion 
channel drug discovery used classical pharmacological 
approaches, in which profi  ling in animal models, de-
signed to simulate human disease states, was used to op-
timize compound activity, even if the nature of the 
    Abbreviations used in this paper: BPBTS,   N  -  {  [2  ’  -(aminosulfonyl)-
biphenyl-4-yl]methyl  }  -  N    ’  -(2,2  ’  -bithien-5-ylmethyl)succinimide; FRET, 
fl  uorescence resonance energy transfer; HTS, high throughput screen-
ing; Nav, voltage-gated sodium channel; PNS, peripheral nervous sys-
tem; UHTS, ultra HTS. 
molecular target was unclear. Serendipity, insight, and 
brute force effort drove these drug discovery efforts and 
resulted in a number of notable successes including suc-
cessful therapies and discovery of research tools that 
have been invaluable in mapping out signaling path-
ways, purifying channel proteins, and characterizing 
gating mechanisms, all of which has sustained the pres-
ent era of ion channel drug discovery (  Garcia and 
Kaczorowski, 2005  ). 
  With the advent of a more complete understanding 
of cellular physiology and identifi  cation of the molecu-
lar components that constitute individual channel types 
and control their function, researchers are now focus-
ing on a molecular-based strategy to identify drugs tar-
geting this protein class. The molecular approach has 
been signifi  cantly strengthened by the advent of new 
technologies, including high throughput screening 
capabilities and automated electrophysiology. Despite 
these advances, the discovery and development of new 
ion channel drug candidates remains an arduous task. 
Signifi  cant challenges exist in the validation of new tar-
gets, which may be hindered by complex and potentially 
species-specifi  c physiology (  Yu and Catterall, 2004  ), dif-
fi  culties in discovering acceptable small molecule leads, 
and the lack of biomarker and target engagement strat-
egies to validate that drug exposure in patients is suffi  -
cient to differentiate negative from failed clinical trails. 
Each of these challenges is addressed in more detail in 
the remainder of this article, using examples from a drug 
discovery effort on voltage-gated sodium channels. 
  Identiﬁ  cation and Validation of Ion Channel Targets 
  Drug discovery and development is a costly and time 
consuming process which, unfortunately, often meets 
with limited success. Issues that contribute to program 
failure include toxicity, due to the interaction of a devel-
opment candidate with unrelated channels or other 
proteins (e.g., inhibition of Kv11.1, potentially leading 
to life threatening arrhythmias;   Ashcroft, 2000  ), and se-
lection of inappropriate targets due to uncertainties re-
garding the predictive nature of animal models used for 
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antidepressants, such as amitriptyline, which are effi  ca-
cious in treating neuropathic pain, possess a broad 
spectrum of pharmacological activities including in-
hibition of Nav1 channels. A comparison between ther-
apeutic effi  cacy and ability to inhibit Nav1.7 channels 
for two classes of antidepressants, tricyclics and sero-
tonin reuptake inhibitors, suggests a role of sodium 
channel inhibition in the effi  cacy of these compounds 
in treating neuropathic pain (  Dick et al., 2007  ). Tricyclic 
antidepressants were potent sodium channel inhibitors 
and their potency in binding to the inactivated state 
of Nav1.7 was within the range of plasma concentra-
tions required for the treatment of neuropathic pain. 
In contrast, antidepressant serotonin reuptake inhibi-
tors that are not effective in treating post-herpetic neu-
ralgia or diabetic neuropathy were weaker inhibitors of 
Nav1.7, with in vitro potencies mostly above their thera-
peutic concentration ranges. These data suggest that 
inhibition of voltage-gated sodium channels may con-
tribute to the anti-hyperalgesic effi  cacy of tricyclic anti-
depressants and is further support for targeting sodium 
channels to treat chronic pain with more potent and 
selective inhibitors. 
  Another example of pharmacological validation comes 
from the use of peptides, such as Ziconotide, a synthetic 
analogue of a peptide contained in cone snail venom, 
and a potent blocker of the N-type voltage-gated cal-
cium channel, Cav2.2 (  Miljanich, 2004  ). Ziconotide was 
developed clinically as a treatment for intractable pain 
by intrathecal administration. In vivo pharmacological 
results with Ziconotide strongly support the hypothesis 
that a systemic small molecule inhibitor of Cav2.2 
should be useful for treating pain. Similarly, in vitro stud-
ies with the spider toxin peptide GxTX demonstrate 
that the pancreatic      cell delayed rectifying potassium 
channel, Kv2.1 (KCNB1) is a potential target for en-
hancing glucose-dependent insulin secretion, and thus 
for the treatment of type II diabetes (  Herrington et al., 
2006  ). Since peptidyl modulators of ion channels are 
abundant in venoms, they are rich sources for reagents 
useful in proof of concept studies. In addition, small 
molecule natural product channel modulators, including 
indole diterpene blockers of high conductance, calcium-
activated potassium channels (KCNMA1), have been 
used as probes in target validation studies (  Garcia and 
Kaczorowski, 2001  ). 
  Lead Identiﬁ  cation and Characterization 
  The most challenging aspect of ion channel drug dis-
covery may be the identification of an appropriate, 
small molecule drug lead with desirable chemical prop-
erties that qualify it for exploration by medicinal chem-
istry (  MacCoss and Baillie, 2004  ). This is a key element 
in successful ion channel preclinical drug development. 
Ion channels have traditionally been considered diffi  -
cult targets to engage in high throughput functional 
preclinical testing when compared with human patho-
physiology. An essential route to increased success in 
ion channel drug discovery is rigorous application of 
traditional and novel in vitro and in vivo target valida-
tion approaches, including genetic and pharmacologi-
cal validation studies, expression profi  ling, and altering 
channel expression in model systems. Improvements in 
the target identifi  cation and validation stage can, argu-
ably, have the greatest overall impact on ion channel 
drug discovery efforts. 
  Human genetics and gene ablation studies in rodents 
have identifi  ed a number of new ion channel targets 
(e.g., Nav1.7, Nav1.4, Cav2.2, KCNMA1, Kir1.1, Kir6.2-
SUR2, KCNQ, etc.) (  Ashcroft, 2000  ;   Lifton et al., 2001  ; 
  Yu and Catterall, 2004  ;   Dib-Hajj et al., 2007  ). In addi-
tion to traditional knockout techniques, modulation of 
channel expression by regulation of promotor activity, 
siRNA technology, or the employment of dominant-
negative interference strategies can be used to aid in 
the validation of novel targets. 
  As an example of human genetic validation, recent 
evidence has pointed to Nav1.7 as the most promising 
sodium channel target for new analgesics (  Dib-Hajj 
et al., 2007  ). The syndrome of Congenital Indifference 
to Pain has been linked to nonsense mutations in Nav1.7 
in individuals from 12 families representing 8 nationali-
ties. These individuals have a complete inability to sense 
pain, and yet they appear normal in all other respects, 
including intelligence, physical development, motor and 
autonomic refl  exes, and sensation with the exception 
of the sense of smell. Additionally, several human gain 
of function mutations have been identified in Nav1.7 
channels and shown to be linked to inherited pain dis-
orders such as Inherited Erythromelalgia or Paroxysmal 
Extreme Pain Disorder (  Dib-Hajj et al., 2007  ). Interest-
ingly, the human loss of Nav1.7 function was not repli-
cated in mice, where a conventional knockout is lethal, 
and a nociceptor-specifi  c knockout (  Nassar et al., 2004  ) 
develops normally but displays a mild pain phenotype 
(resistance to infl  ammatory pain). 
  Given the possibility of compensatory changes in ge-
netically derived disease models, the most convincing 
target validation is derived from pharmacological proof 
of concept in an animal model refl  ecting human physi-
ology. Such validation can be obtained through use of 
existing small molecule channel modulators, peptide 
neurotoxins, or antibodies specifi  cally developed to 
inhibit channel function. Specifi  c examples of target 
validation using existing drugs (lidocaine, tricyclic anti-
depressants) or peptides (Ziconotide and GxTX) are 
discussed below. 
  Systemic administration of the local anesthetic lido-
caine is approved for the treatment of neuropathic pain 
(  Priest and Kaczorowski, 2007  ). At clinically used con-
centrations, block of Nav1 channels appears to be the 
only mode of action of this agent. Similarly, tricyclic     Kaczorowski et al.  401
formats are amenable to application of ultrahigh 
throughput automation strategies. 
  Until recently, the characterization of screening hits 
using manual voltage clamp techniques was slow and te-
dious, because of the low throughput inherent to this 
technique. However, secondary screening of initial hits 
has now been revolutionized with the use of new auto-
mated patch clamp technologies that can confi  rm a 
compound  ’  s direct functional effects on the channel, 
determine its selectivity across superfamilies of ion 
channels, and provide mechanistic insights, all accom-
plished in a very rapid fashion. Several different plat-
forms are commercially available with specifi  c features 
determining their optimal application, from specializ-
ing in high throughput analysis to more quantitative 
measurements of channel activity using complex volt-
age protocols (  Priest et al., 2007  ). Hopefully, automated 
patch clamp technologies will soon be adapted to UHTS 
requirements, enabling a new set of UHTS approaches 
toward fi   nding novel ion channel modulators. Pres-
ently, the combination of biochemical and biophysical 
approaches is needed to identify useful lead structures. 
Together, these strategies, along with more classical drug 
development techniques, provide a means for discovering 
and optimizing the activity of potential ion channel 
drug development candidates for almost any member 
of the various ion channel super families. 
  Case Study: Discovering Inhibitors of Voltage-gated 
Sodium Channels 
  As a way of illustrating the issues related to ion channel 
drug discovery outlined above, the remainder of this ar-
ticle will describe a case study focusing on the identifi  ca-
tion of voltage-gated sodium channel inhibitors to treat 
chronic neuropathic pain. Treatment of pain is a seri-
ous medical issue and there is a major effort in the phar-
maceutical industry to develop new therapies for this 
condition. In particular, the treatment of neuropathic 
pain, defi  ned as   “  chronic pain that results from a pri-
mary lesion or dysfunction of the peripheral nervous 
system  ”   by the International Association for the Study of 
Pain (IASP), remains a major unmet medical need. 
  It is clear that voltage-gated sodium (Nav1) channels 
play a key role in the origination and propagation 
of sensory nerve action potentials necessary for pain 
signaling. Local applications of nonsubtype-selective 
sodium channel blockers, such as novocaine, provide 
complete pain relief through conduction block. How-
ever, this approach to pain relief is limited to very few 
applications, such as dental procedures, since sodium 
channels are also vital to conduction in the heart, CNS, 
skeletal muscle, and nonnociceptive sensory neurons. 
The Nav1 super family is comprised of 10 members (  Yu 
and Catterall, 2004  ). Seven of these subtypes, Nav1.1, 
Nav1.3, Nav1.5, Nav1.6, Nav1.7, Nav1.8, and Nav1.9, are 
present in the peripheral nervous system (PNS). Of these, 
screening formats, and large scale screening campaigns 
have often yielded a paucity of potent, selective hits. 
The scarceness of acceptable ion channel leads may 
derive from the long-standing emphasis within the 
pharmaceutical industry on programs directed at G 
protein  –  coupled receptors, kinases, and other enzymes, 
leading to biased sample collections. Successful target-
ing of ion channels critically requires robust and sensi-
tive, mechanism-based, HTS technologies that can 
detect a vanishingly small number of actives in large 
compound libraries, or in other words, can   “  fi  nd a nee-
dle in a haystack  ”   (  Herrington et al., 2005  ;   Garcia and 
Kaczorowski, 2006  ). Implementation of reliable and in-
formative counter-screens for likely off-target activities is 
essential for meaningful hit assessment and lead prioritiza-
tion to ensure that resources are not wasted in pursuing 
nondevelopable chemical structures. Recent introduc-
tion of fl  uorescent, cell-based screening technologies 
has enabled dependable HTS and ultra high through-
put screening (UHTS) paradigms, allowing screening 
of libraries consisting of millions of compounds in 
a timely, cost effective manner, and thereby allow de-
tection of true lead structures with adequate initial po-
tency, selectivity across ion channel superfamilies, and 
defi  ned mechanisms of action. Early mechanistic stud-
ies are also important, since a particular mechanism of 
action may lead to functional selectivity for the target 
channel through state dependence and/or use-dependent 
channel inhibition. 
  In one general confi  guration, HTS assays can be insti-
tuted for many different types of ion channels by estab-
lishing cell lines heterologously expressing the target in 
a context where changes in the activity of the channel 
of interest can affect the cellular plasma membrane po-
tential. Potential sensitive fl  uorescent dyes can then be 
used to monitor changes in membrane potential of 
such cells grown in high density, multiwell format plates 
during screening procedures (  Gonzalez and Maher, 
2002  ). Detection of an active compound is achieved if 
addition of test compound causes a corresponding 
change in membrane potential. This strategy works well 
to identify sodium or potassium channel modulators, 
and such paradigms can be used to screen for ligand-
gated ion channel modulators, as well. Identifi  cation of 
both channel inhibitors and channel openers can be 
accomplished using this general screening method 
(  Garcia et al., 2007  ). For detecting voltage-gated calcium 
channel effectors, a similar approach can be adopted, 
except that fl  uorescent dye indicators are employed 
to monitor the concentration of intracellular calcium. 
Cotransfection with an inwardly rectifying potassium chan-
nel, together with the controlled variation in extracellu-
lar potassium concentration, has been used to control 
cellular membrane potential, in order to establish the 
most sensitive and mechanistically meaningful assay 
confi  guration (  Xia et al., 2004  ). All of these screening 402   The Next GPCRs 
testing compounds of interest on Nav1.7, Nav1.5 (the 
primary cardiac sodium channel) and Nav1.8 in parallel. 
  A membrane potential  –  based assay was used to screen 
    200,000 compounds on Nav1.8 stably expressed in a re-
combinant cell line. This HTS assay was based on fl  uores-
cence resonance energy transfer (FRET) between two 
members of a membrane potential  –  sensitive dye pair de-
veloped by Aurora Biosciences (  Priest et al., 2004  ). Nav1.8 
channels were preincubated with test compound and the 
chemical agonist deltamethrine in the absence of extracel-
lular sodium. Subsequent addition of sodium resulted in 
membrane depolarization and Nav1 block was quantifi  ed 
as interference with that cellular depolarization process. 
  Although the initial screen on Nav1.8 yielded a variety 
of hits, only a single compound was considered a viable 
lead for medicinal chemistry efforts. Before committing 
resources to this lead, the compound, a disubstituted 
succinimide termed BPBTS (  N  -  {  [2  ’  -(aminosulfonyl) 
biphenyl-4-yl] methyl  }  -  N    ’  -(2,2  ’  -bithien-5-yl methyl)
succinimide), was examined in detail by manual whole 
cell voltage clamp. BPBTS was found to inhibit all Nav1 
subtypes with similar potency, and inhibition was depen-
dent on membrane potential and stimulation frequency. 
This inhibitory mechanism was consistent with higher 
affi  nity of the compound for channels in the open and 
inactivated state, compared with channels in the resting 
state. In addition, BPBTS was two orders of magnitude 
more potent than the clinically used anticonvulsant and 
antiarrhythmic Nav1 blockers, inhibiting the inactivated 
state of Nav1.8, Nav1.7, Nav1.5, and Nav1.2, with Ki val-
ues of 0.09, 0.15, 0.08, and 0.14   μ  M and the resting state 
with Kr values of 1.5, 1.3, 0.3, and 1.2   μ  M, respectively 
(  Priest et al., 2004  ). 
Nav1.7, Nav1.8, and Nav1.9 are expressed predomi-
nantly in nociceptive neurons, and Nav1.3 is predomi-
nantly embryonic, but is up-regulated in the adult PNS 
after injury. This limited expression pattern makes these 
subtypes attractive targets for the development of novel 
analgesic agents. However, their relative contribution to 
pain signaling, and specifi  cally to neuropathic pain sig-
naling, is unclear and may vary with different etiologies 
and sensory qualities of pain. 
  In the absence of molecular selectivity for one Nav1 
subtype, it is possible to specifi  cally target Nav1 chan-
nels in a given conformational state while preserving 
sodium channel  –  dependent impulse conduction. This 
type of state-dependent inhibition is the basis for the 
therapeutic window seen with sodium channel blocking 
anticonvulsants and antiarrhythmics, such as lamotrig-
ine and lidocaine. These drugs have higher affi  nity for 
channels in the open and/or inactivated states than for 
resting, closed channels. This mechanism of inhibition 
favors binding in rapidly fi  ring or partially depolarized 
tissues. Neuropathic pain should be sensitive to this in-
hibitory mechanism, since it is thought to arise from in-
jury-induced areas of depolarizations, a hypothesis that 
is supported by the clinical effi  cacy of lidocaine admin-
istered systemically at subanesthetic doses. Moreover, 
nonsubtype-selective, state-dependent block may afford 
the greatest effi  cacy, since individual knockout of Nav1.3, 
Nav1.7, Nav1.8, or Nav1.9 did not provide convincing 
evidence for a dominant role of any of these channels 
in neuropathic pain signaling. 
  Based on this rationale, a decision was made to ini-
tially pursue nonsubtype selective, state-dependent Nav1 
inhibitors, while monitoring molecular selectivity by 
  Figure 1.     A functional, membrane potential 
FRET-based assay for Nav1.7 channels. In the 
absence of other ionic conductances that can 
hyperpolarize the cell, heterologous expression 
of Nav1.7 channels provides a system where at 
the cell resting membrane potential most chan-
nels will reside in the nonconducting inactivated 
state. Removal of fast inactivation by the addition 
of veratridine shifts the channel  ’  s equilibrium 
to the conductive, open state that allows sodium 
entry leading to cell depolarization. The changes 
in voltage can be monitored with a pair of FRET 
voltage-sensing dyes, coumarin and oxonol. Cell 
depolarization alters the distribution of oxonol 
across the membrane, causing a change in the 
FRET signal. In the presence of a Nav1.7 inhibi-
tor, channel equilibrium shifts toward the inac-
tivated, drug-bound conformation, reducing 
the number of channels that will be available 
for veratridine modifi   cation, and preventing 
the agonist-induced FRET signal. The dose  –  re-
sponse curve for the veratridine-induced change 
in FRET signal is steep, suggesting that modifi  ca-
tion of a small number of Nav1.7 channels is suf-
fi  cient to cause cell depolarization.         Kaczorowski et al.  403
with a brain to plasma ratio greater than 10 for mexi-
letine. These data obtained with CDA54 strongly sug-
gested that inhibition of PNS sodium channels alone 
is effi  cacious in animal models of neuropathic pain, 
and that limiting CNS exposures of Nav1 inhibitors is 
a viable approach to developing Nav1 inhibitors with 
an improved therapeutic index. 
  A UHTS campaign, using the membrane potential  –
  based assay described to screen for inhibitors of Nav1.7, 
discovered the novel 1-benzazepin-2-one channel inhibi-
tors (  Hoyt et al., 2007  ;   Williams et al., 2007  ). This class of 
inhibitors demonstrated a defi  ned structure–activity rela-
tionship and, when evaluated in vivo, members of this se-
ries were orally effi  cacious in rodent neuropathic pain 
and epilepsy models. Importantly, some members of this 
class displayed molecular selectivity for Nav1.7 channels 
(  Williams et al., 2007  ). For example, compound 2 of   Fig. 2   
was highly state dependent and     10-fold selective for 
Nav1.7 over Nav1.8 and Nav1.5.   The most potent, albeit 
not subtype-selective, member of this class of Nav1.7 in-
hibitors (compound 1, BNZA;   Fig. 2  ) was tritiated. 
[ 
3  H]BNZA binds with high affi  nity (Kd of 1.6 nM) to re-
combinant Nav1.7 channels. This is the fi  rst demon-
stration of high-affi  nity ligand binding to Nav1.7 and 
provides a valuable screening tool with which to search 
for Nav1.7-selective compounds. Data obtained with the 
1-benzazepin-2-one structural series suggest that Nav1.7-
selective analogues can be identifi  ed, and with the 
appropriate pharmacokinetic and drug metabolism 
properties, such compounds could be developed as anal-
gesic agents, potentially displaying improved tolerability 
over existing drugs used to treat neuropathic pain. Sup-
port for the feasibility of developing subtype-selective so-
dium channel inhibitors as novel analgesics comes from 
the recent report of a high affi  nity Nav1.8 selective agent, 
which given intraperitoneally was effi  cacious in a wide 
range of rodent pain models (  Jarvis et al., 2007  ). 
  A potential alternative approach to searching for sub-
type-selective sodium channel inhibitors would be to 
screen for compounds that target channel gating mech-
anisms. Several peptides have previously been shown to 
  As such, BPBTS was an attractive lead for medicinal 
chemistry; its main liabilities being a poor pharmacoki-
netic profi  le. Over the course of profi  ling analogues of 
BPBTS, as well as published Nav1 inhibitors, using the 
membrane potential  –  based fl  uorescent screening assay, 
structure-based discrepancies between potencies deter-
mined in the fl  uorescent assay and by electrophysiology 
were noted for a few compounds. These discrepancies 
were traced to an interaction between these compounds 
and the agonist veratridine used to open Nav1.7 chan-
nels. Subsequently, the fl  uorescent assay was modifi  ed 
such that Nav1 channels were preincubated with test com-
pound in physiological extracellular sodium concen-
trations and Nav1-dependent depolarization was initiated 
by agonist addition (  Fig. 1  ).   Channel inhibitory poten-
cies measured in this modifi  ed assay correlated very 
well with the inactivated state inhibition determined 
by electrophysiology across many structural classes of 
Nav1 inhibitors (  Felix et al., 2004  ;   Liu et al., 2006  ). 
  Although analogues of BPBTS failed to surpass the 
initial lead in potency, medicinal chemistry succeeded 
at improving the pharmacokinetic profile, eventu-
ally generating trans-  N  -  {  [2  ’  -(aminosulfonyl)biphenyl-
4-yl]methyl  }  -  N  -methyl-  N    ’  -[4-(trifl  uoromethoxy)benzyl]
cyclopentane-1,2-dicarboxamide (CDA54) with 44% oral 
bioavailability, one hour half life, and a clearance rate 
of 14 ml/min/kg, which was profi  led extensively in vivo 
(  Brochu et al., 2006  ). In two rat models of neuropathic 
pain, CDA54 (10 mg/kg, given orally) signifi  cantly re-
duced nerve injury  –  induced behavioral hypersensitiv-
ity by 44  –  67%. The same dose/plasma concentration 
of CDA54 did not affect acute nociception (rat hot 
plate assay), motor coordination (rat rotorod assay), or 
cardiac conduction (electrophysiological parameters 
measured in the cardiovascular dog). These properties 
are in contrast to those of current sodium channel block-
ers used in the clinic, which cause impaired motor co-
ordination in rats and CNS side effects in man at all 
effi  cacious doses. Interestingly, upon oral dosing, the 
brain to plasma ratio for CDA54 was 0.03. In contrast, 
clinically used Nav1 blockers accumulate in the CNS, 
  Figure 2.     1-Benzazepin-2-one Nav1 inhibitors. 
The structures of two 1-benzazepin-2-one Nav1 
inhibitors are illustrated together with their po-
tencies for hNav1.5, hNav1.7, and hNav1.8 chan-
nels as determined in functional membrane 
potential, FRET-based assays. The estimated po-
tencies of these compounds for the inactivated 
state of hNav1.5 and hNav1.7 channels, as de-
termined from electrophysiological recordings, 
are also presented. Note that only compound 
2 displays selectivity for the hNav1.7 channel. 
Both compounds are weaker inhibitors of the 
hNav1.8 channel.     404   The Next GPCRs 
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modify gating of sodium channels, but few small mole-
cules, especially inhibitors, have been described to 
function in this fashion. One such agent is ProTx-II, a 
30  –  amino acid peptide purifi  ed from tarantula venom; 
this peptide blocks sodium channels and shows selectiv-
ity for Nav1.7 (  Smith et al., 2007  ). ProTx-II binds to the 
resting state of sodium channels and shifts the voltage 
dependence of channel activation to more depolarized 
potentials. Strong depolarizations overcome channel 
inhibition, which is a hallmark of this type of gating 
modifi  er peptide. One possible strategy to identify small 
molecule mimetics of a gating modifi  er peptide is to ra-
diolabel ProTx-II in biologically active form, and to 
develop a binding assay with Nav1.7 channels heterolo-
gously expressed in a cell line. Screening for small mol-
ecules that modulate ProTx-II binding could reveal new 
classes of channel inhibitors that partition into the 
membrane and interfere with movement of the gating 
paddle, thereby preventing channel opening. An added 
advantage of this type of UHTS is that high concentra-
tions of test compounds could be employed, a situation 
that is precluded in dye-based screening due to fl  uores-
cence interference that typically occurs with high con-
centrations of many small organic molecules. Given that 
some gating modifi  er peptides bind to regions that 
are unique to specifi  c channels within a super family, 
subtype-selective inhibitors might be identifi  ed using 
such a strategy. 
  Conclusions 
  Although identifi   cation of novel sodium channel 
inhibitors was used to illustrate current molecular 
approaches to ion channel drug discovery, these prin-
ciples can be generalized to any ion channel target. 
It would appear that establishment and orchestration 
of functional UHTS is no longer the rate-determin-
ing step in ion channel drug development. Rather, 
the synthesis of ion channel friendly small molecule 
libraries to facilitate lead discovery, and the establish-
ment of meaningful clinical paradigms, including 
development of target engagement indices, to test 
rigorously an agent  ’  s therapeutic potential in man, 
are now the key elements to focus on in order to 
make development of new ion channel drugs a suc-
cessful enterprise. 
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